Disclosure
SAI summary · Not investment advice
Samsung Bioepis posted Q3 2026 consolidated revenue of KRW 442.2 billion and operating profit of KRW 132.6 billion, both up from a year earlier and the prior quarter.
Commentary
AI commentary · Not investment advice
What happened
Samsung Epis Holdings released preliminary consolidated results for its subsidiary Samsung Bioepis Co., Ltd. for the third quarter of 2026, covering July 1 to September 30, through a fair disclosure filed on October 28, 2026. Revenue was KRW 442.2 billion, operating profit was KRW 132.6 billion, and net income was KRW 117.0 billion.
In the company's terms
Against the prior quarter, revenue of KRW 392.2 billion rose 12.8%, operating profit of KRW 86.6 billion rose 53.2%, and net income of KRW 106.7 billion rose 9.6%. Against the same quarter a year earlier, revenue of KRW 441.0 billion rose 0.3% and operating profit of KRW 129.0 billion rose 2.8%, while net income of KRW 121.6 billion fell 3.8%. The filing lists the figure as 1.7% relative to market capitalization.
Earlier filings of the same type
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.10.282026.10.28 | KRW 105.1 billion · No year-over-year comparison (company not yet established) |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist